OakChart

Mirum Pharmaceuticals Inc

MIRMHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 2:25 PM ET

94.36-0.06 (-0.07%)
2026-11-11 20:26 CET
Market cap
6,163.93 USD m
Revenue, TTM
670.78 USD m
Net income, TTM
-903.88 USD m
Free cash flow, TTM
-273.85 USD m
EPS diluted, TTM
-15.22
P/E
-
Compare

Price

MIRM against its 20, 50 and 200-day averages
2050200miss
80.00100.00120.003.3M6.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MIRMclose 94.3620-day 87.0950-day 89.05200-day 98.4994.3652w high

27.4% under the 52-week high of 130.00 on 9 Jul 2026. 52-week low 63.23 on 15 Dec 2025. Last 15 sessions, 23.3% high to low

Profile

MIRM
52-week range, 47% of the way up
63.23130

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

IndexRUT
Employees372
IPOJul 18, 2019
Beta0.73
ATR, 14d4.10
Rel volume0.39
Short float12.06%
Insider own17.16%
Inst own94.60%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap6.16B
Enterprise Value6.53B
Income-903.88M
Sales670.78M
Book/sh-0.83
Cash/sh5.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees372
IPOJul 18, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S9.18
P/B-
P/C16.48
P/FCF-
EV/EBITDA-
EV/Sales9.73
Quick Ratio1.98
Current Ratio2.07
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-15.22
EPS next Y-1.25
EPS next Q-0.62
EPS this Y-3129.70%
EPS next Y91.79%
EPS next 5Y-
EPS past 3/5Y51.26% 35.25%
Sales past 3/5Y89.13% -
EPS Y/Y TTM-1679.32%
Sales Y/Y TTM42.18%
EPS Q/Q-1319.80%
Sales Q/Q39.63%
EarningsNov 03 AMC
EPS/Sales Surpr.-78.72% 4.29%

Ownership

Insider Own17.16%
Insider Trans-1.75%
Inst Own94.60%
Inst Trans3.95%
ROA-99.78%
ROE-760.01%
ROIC-131.61%
Gross Margin81.65%
Oper. Margin-20.88%
Profit Margin-134.75%
SMA208.34%
SMA505.96%
SMA200-4.20%
Trades-

Technical

Shs Outstand65.21M
Shs Float54.08M
Short Float12.06%
Short Ratio9.45
Short Interest6.52M
52W High130.00 -27.42%
52W Low63.23 49.22%
Volatility7.23% 4.69%
ATR (14)4.10
RSI (14)61.42
Beta0.73
Rel Volume0.39
Avg Volume690.26K
Volume205,192

Performance

Perf Week-2.70%
Perf Month18.51%
Perf Quarter-4.47%
Perf Half Y-13.56%
Perf YTD19.45%
Perf Year32.30%
Perf 3Y229.80%
Perf 5Y491.20%
Perf 10Y-
Recom1.13
Target Price155.71
Prev Close94.42
Price94.36
Change %-0.07%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 02, 2026InitiatedCCitigroupBuy$145+53.7%
May 19, 2026InitiatedWWolfe ResearchOutperform$145+53.7%
Feb 18, 2026InitiatedRRBC Capital MktsOutperform$130+37.8%
Sep 24, 2025InitiatedTTD CowenBuy$95+0.7%
Aug 11, 2025ResumedSStifelBuy$89-5.7%
May 19, 2025ResumedHH.C. WainwrightBuy$73-22.6%
Apr 17, 2024InitiatedSStifelBuy$48-49.1%
Dec 18, 2023ReiteratedHH.C. WainwrightBuy$60 → $58-38.5%
Nov 20, 2023ResumedJJP MorganOverweight$37-60.8%
Nov 13, 2023InitiatedMMorgan StanleyOverweight$60-36.4%

Peers

Mkt cap
TickerCompanyMkt cap
MDGLMadrigal Pharmaceuticals Inc10.04B
VIRVir Biotechnology Inc2.25B
TVTXTravere Therapeutics Inc4.99B
PTCTPTC Therapeutics Inc5.37B
RYTMRhythm Pharmaceuticals Inc7.96B
RAREUltragenyx Pharmaceutical Inc1.71B
IVAInventiva ADR949.23M
GILDGilead Sciences Inc210.40B
ZVRAZevra Therapeutics Inc708.70M
BCRXBiocryst Pharmaceuticals Inc1.97B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Peetz ChristopherCHIEF EXECUTIVE OFFICERNov 04 '26Option Exercise2.9420,00058,720226,637Nov 04 08:46 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERNov 04 '26Sale90.0020,0001,800,000206,637Nov 04 08:46 PM
Joanne QuanFormer OfficerNov 04 '26Proposed Sale96.9714,6841,423,907Nov 04 08:41 PM
CHRISTOPHER PEETZOfficerNov 04 '26Proposed Sale90.0020,0001,800,000Nov 04 04:26 PM
Howe JolandaSVP, GLOBAL CONTROLLEROct 16 '26Option Exercise19.2416,112309,99516,728Oct 19 04:10 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICEROct 06 '26Option Exercise17.3112,197211,179206,637Oct 06 08:38 PM
ERIC BJERKHOLTOfficerSep 14 '26Proposed Sale98.379,943978,093Sep 15 04:18 PM
BJERKHOLT ERICCHIEF FINANCIAL OFFICERSep 14 '26Sale98.379,943978,09344,745Sep 15 04:10 PM
Howe JolandaSVP, GLOBAL CONTROLLERSep 02 '26Sale100.0065865,800616Sep 03 06:54 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERSep 01 '26Option Exercise2.9430,00088,080224,440Sep 03 06:52 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERSep 01 '26Sale98.6830,0002,960,401194,440Sep 03 06:52 PM
JOLANDA MARIE HOWEOfficerSep 02 '26Proposed Sale100.0065865,800Sep 02 04:06 PM
CHRISTOPHER PEETZOfficerSep 01 '26Proposed Sale98.6830,0002,960,319Sep 01 04:12 PM
Howe JolandaSVP, GLOBAL CONTROLLERAug 18 '26Option Exercise6.2740,000250,80041,274Aug 19 06:19 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.870-0.487-0.870185.72178.0813
2026Q22026-08-05-1.060-0.743-1.061176.2166.3313
2026Q12026-05-06-13.430-0.365-13.426159.9148.219
2025Q42026-02-25-0.1000.056-0.111148.93142.510
2025Q32025-11-040.050-0.1400.051133.01130.510
2025Q22025-08-06-0.120-0.326-0.118127.79108.119
2025Q12025-05-07-0.300-0.330-0.300111.5998.419
2024Q42025-02-26-0.490-0.258-0.49599.4196.619
2024Q32024-11-12-0.300-0.449-0.29890.3881.9910
2024Q22024-08-07-0.520-0.472-0.52277.8875.0310
2024Q12024-05-08-0.540-0.420-0.53969.2270.139
2023Q42024-02-28-0.630-0.240-0.71069.5567.879
2023Q32023-11-02-0.570-0.628-0.57447.7338.607
2023Q22023-08-03-1.940-0.795-1.94337.5030.445
2023Q12023-05-04-0.800-0.889-0.80031.6028.697
2022Q42023-03-08-0.962-1.004-0.99227.9124.658

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.580-3.855-2.2860.000.00
2020FY-4.090-3.355-4.0900.0010.00
2021FY-2.770-4.481-2.77019.1478.42
2022FY-4.020-4.034-4.01977.0676.00
2023FY-3.940-3.369-3.997186.37184.64
2024FY-1.850-1.613-1.851336.89334.42
2025FY-0.470-0.246-0.470521.31515.52
2026FY--15.180--715.85
2027FY--1.247--869.74
2028FY-1.893--1,157
2029FY-6.065--1,578
2030FY-9.799--2,044

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1012110194.47182197.54
2026Q4S2026-11-0912110194.47182197.54
2026Q4S2026-11-0412110194.47182197.54
2026Q4S2026-11-031201184.01174.6191.1
2026Q4S2026-10-231201184.01174.6191.1
2026Q4S2026-10-201201184.01174.6191.1
2026Q4S2026-10-161291183.96174.6191.1
2026Q4S2026-10-131291183.87174.6190.2
2026Q4S2026-10-071291183.86174.6190.2
2026Q4S2026-09-281291183.81174.6190.2
2026Q4S2026-09-2512100183.98176.6190.2
2026Q4S2026-08-2612100183.81176.6190
2026Q4S2026-08-1912100183.81176.6190
2026Q4S2026-08-1012100183.81176.6190

Estimate history

EPS, annual-0.755-2.286-4.09-2.77-4.019-3.997-1.851-0.465-15.2203
Period20182019202020212022202320242025TTM
EPS, quarterly-0.298-0.495-0.3-0.1180.051-0.111-13.426-1.061-0.622
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00019.13877.062186.374336.888521.312670.78
Period20182019202020212022202320242025TTM
Sales, quarterly90.37799.414111.585127.785133.01148.932159.882176.243185.721
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual22.9922.9929.77730.58336.95646.72348.33851.89665.209
Period20182019202020212022202320242025MRQ
Shares, quarterly47.96848.33849.45150.05851.31451.89660.92664.75565.209
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue670.78521.31336.89186.3777.0619.140.000.000.00
Cost of Goods Sold Incl. D&A123.06100.5882.1747.3712.712.240.620.320.00
Gross Profit547.72420.73254.72139.0164.3516.90-0.62-0.320.00
Selling, General and Administrative Excl. Other687.79442.86342.32248.16195.57190.31103.6754.422.92
Research and Development347.00185.83140.10102.28106.50131.0981.3042.992.33
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-140.08-22.14-87.61-109.15-131.22-173.41-104.30-54.74-2.92
Interest Expense11.4414.3914.3115.1115.9817.590.340.000.01
Unusual Expense784.640.000.0049.08-1.820.730.000.0014.49
Net Income Before Taxes-900.41-21.43-86.91-162.42-142.07-83.95-103.26-52.53-17.35
Income Taxes3.471.941.030.99-6.410.040.010.020.00
Consolidated Net Income-903.88-23.36-87.94-163.41-135.66-83.99-103.27-52.55-17.35
Net Income From Continuing Operations-903.88-23.36-87.94-163.41-135.66-83.99-103.27-52.55-17.35
Net Income-903.88-23.36-87.94-163.41-135.66-83.99-103.27-52.55-17.35
EPS (Recurring)-5.41-0.47-1.85-3.16-4.07-2.75-4.09-2.29-0.31
EPS (Basic, Before Extraordinaries)-15.22-0.47-1.85-4.00-4.01-2.77-4.09-2.29-0.75
EPS (Diluted)-15.22-0.47-1.85-4.00-4.02-2.77-4.09-2.29-0.75
EBITDA-113.312.11-63.98-98.33-127.54-172.44-103.67-54.42-2.92
Non-Operating Income (Expense)35.7415.1015.0110.913.31107.781.372.210.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense110.9056.4238.2727.6721.3416.809.164.430.03
Price To Sales Ratio8.357.615.836.488.5625.27---
Gross Margin81.6580.7175.6174.5883.5088.31---
Operating Margin-20.88-4.25-26.00-58.57-170.28-906.12---
Net Margin-134.75-4.48-26.10-87.68-176.05-438.85---
Shares Outstanding65.2151.9048.3446.7236.9630.5829.7822.9922.99
Market Capitalization6,163.936,163.931,984.991,376.05718.97488.68514.49563.71573.60

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue185.72176.24159.88148.93133.01127.78111.5899.41
Cost of Goods Sold Incl. D&A35.2630.5828.8828.3425.6023.5823.0722.84
Gross Profit150.46145.66131.00120.59107.41104.2188.5276.58
Selling, General and Administrative Excl. Other196.71171.76194.17125.16104.81109.20103.70100.80
Research and Development107.8490.2997.8451.0342.9045.9145.9943.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-46.25-26.10-63.16-4.572.60-4.99-15.18-24.22
Interest Expense1.612.623.623.603.613.593.603.58
Unusual Expense30.0029.33725.300.000.000.000.000.00
Net Income Before Taxes-40.23-65.54-789.68-4.962.64-5.46-13.65-24.37
Income Taxes0.541.690.470.77-0.260.401.03-0.58
Consolidated Net Income-40.77-67.23-790.15-5.732.90-5.86-14.68-23.79
Net Income From Continuing Operations-40.77-67.23-790.15-5.732.90-5.86-14.68-23.79
Net Income-40.77-67.23-790.15-5.732.90-5.86-14.68-23.79
EPS (Recurring)-0.30-0.74-4.80-0.110.05-0.12-0.30-0.49
EPS (Basic, Before Extraordinaries)-0.62-1.06-13.43-0.110.06-0.12-0.30-0.49
EPS (Diluted)-0.62-1.06-13.43-0.110.05-0.12-0.30-0.49
EBITDA-39.36-19.17-56.291.518.661.07-9.13-18.17
Non-Operating Income (Expense)37.62-7.492.403.203.653.125.133.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense26.3124.1545.4015.0314.3214.5912.4810.47
Price To Sales Ratio8.3512.009.547.828.865.905.815.90
Gross Margin81.0182.6581.9480.9780.7581.5579.3377.03
Operating Margin-24.90-14.81-39.51-3.071.96-3.90-13.61-24.36
Net Margin-21.95-38.14-494.21-3.852.18-4.59-13.15-23.93
Shares Outstanding65.2164.7560.9351.9051.3150.0649.4548.34
Market Capitalization6,163.937,139.075,574.364,082.503,682.922,520.822,208.091,984.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments383.33280.31286.33151.72156.54231.82116.6651.96
Short Term Receivables123.3378.2967.9723.994.370.000.000.00
Inventories24.8922.4022.315.571.510.000.000.00
Other Current Assets18.1411.7810.948.954.174.532.700.01
Total Current Assets549.68392.79387.54190.22166.59236.35119.3651.98
Net Property, Plant & Equipment10.609.811.992.352.553.243.730.00
Total Investments and Advances9.5912.950.00100.00104.980.0023.290.00
Intangible Assets260.92249.82252.9358.9518.74--0.00
Other Assets12.025.384.171.381.791.270.320.00
Total Assets842.81670.75646.62352.91294.65240.86146.7151.98
Short Term Debt Incl. Current Port. of LT Debt2.141.711.100.930.710.640.400.00
Accounts Payable9.6114.627.428.699.173.153.350.27
Other Current Liabilities194.05110.2278.5455.1132.7214.689.332.18
Total Current Liabilities205.80126.5587.0664.7342.6018.4613.082.45
Long Term Debt317.31316.05307.04141.61131.8350.283.250.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities5.012.513.854.530.020.030.040.00
Total Liabilities528.12445.11397.95210.87174.4468.7716.362.45
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.0066.84
Common Equity314.69225.64248.67142.04120.21172.09130.35-17.31
Total Shareholders Equity314.69225.64248.67142.04120.21172.09130.3549.53
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity314.69225.64248.67142.04120.21172.09130.3549.53
Total Liabilities & Stockholders Equity842.81670.75646.62352.91294.65240.86146.7151.98
Book Value Per Share6.064.675.323.843.935.785.67-0.75
Tangible Book Value Per Share1.04-0.50-0.092.253.325.785.67-0.75
Full-Time Employees3723222641961376833-
Price to Book Ratio-113.638.555.114.244.063.024.323.92
Return on Assets-3.09-13.35-32.70-41.90-31.37-53.29-52.90-
Return on Equity-8.65-37.08-83.65-103.46-57.47-68.29-58.43-
Return on Invested Capital-3.70-16.23-29.41-47.83-33.32-46.44-39.34-35.03
Quick Ratio2.552.934.192.853.8812.809.1321.22
Current Ratio2.673.104.452.943.9112.809.1321.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-903.88-23.36-87.94-163.41-135.66-83.99-103.27-52.55-17.35
Depreciation26.7724.2423.6310.833.680.970.620.320.00
Other Funds (Non Cash)546.8874.6652.05104.2832.90-66.7312.965.7414.54
Funds from Operations-330.2275.54-12.27-48.30-99.09-149.74-89.69-46.48-2.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital58.96-19.7122.59-22.64-21.0516.980.617.122.44
Cash from Operating Activities-271.2655.8310.32-70.94-120.14-132.76-89.08-39.36-0.37
Capital Expenditures-37.59-0.95-20.99-20.11-0.28-19.02-0.23-0.28-7.50
Net Assets From Acquisitions0.000.000.00-212.760.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-161.83-23.00-69.13125.677.98-40.4338.10-127.500.00
Purchase of Investments-260.88-97.42-89.03-27.33-132.32-198.03-74.56-152.00-
Sale Or Maturity of Investments99.0574.4219.89153.00140.30157.60112.6624.500.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.00108.000.000.000.00
Cash from Investing Activities-199.42-23.95-90.12-107.207.7048.5537.87-127.78-7.50
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock300.2140.1417.70227.15114.649.01131.71127.1859.79
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock300.2140.1417.70227.15114.649.01131.71127.1859.79
Proceedsfrom Stock Options40.2640.140.00216.68107.379.01131.71127.1859.79
Issuance or Reduction of Debt, Net135.970.000.00109.73-5.5564.4549.580.000.05
Change in Long Term Debt135.970.000.00109.73-5.5564.4549.580.000.05
Issuance of Long Term Debt672.050.000.00305.300.0064.5849.580.000.05
Reduction of Long Term Debt-536.080.000.00-195.58-5.55-0.120.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.280.000.000.000.000.00
Other Financing Activities Uses0.000.000.00-0.280.000.000.000.000.00
Cash from Financing Activities436.1740.1417.70336.60109.0973.47181.29127.1859.84
Exchange Rate Effect-3.073.22-1.30-0.130.01-0.000.03-0.03-
Net Change in Cash-37.5875.24-63.40158.32-3.34-10.75130.12-39.9951.96
Free Cash Flow-273.8554.879.33-71.05-120.41-132.78-89.30-39.64-0.37
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-72.26210.57------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments373.69438.29386.26383.33375.55304.55
Short Term Receivables156.35145.36133.11123.33107.13106.84
Inventories25.4925.7725.5224.8924.0222.94
Other Current Assets31.1126.8924.5518.1423.8719.07
Total Current Assets586.63636.31569.44549.68530.58453.40
Net Property, Plant & Equipment14.6114.2815.0610.609.7810.12
Total Investments and Advances128.50124.7636.099.592.9517.59
Intangible Assets275.65247.39254.15260.92231.90237.87
Other Assets21.2322.2416.1812.029.926.84
Total Assets1,026.611,044.98890.92842.81785.12725.83
Short Term Debt Incl. Current Port. of LT Debt2.602.402.352.142.042.08
Accounts Payable13.6523.4359.409.6112.1717.66
Other Current Liabilities266.84196.96211.07194.05146.16125.06
Total Current Liabilities283.08222.79272.82205.80160.36144.80
Long Term Debt740.97760.54321.43317.31316.73316.82
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities56.7572.0754.175.0115.989.05
Total Liabilities1,080.801,055.40648.42528.12493.07470.67
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-54.19-10.42242.49314.69292.05255.16
Total Shareholders Equity-54.19-10.42242.49314.69292.05255.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-54.19-10.42242.49314.69292.05255.16
Total Liabilities & Stockholders Equity1,026.611,044.98890.92842.81785.12725.83
Book Value Per Share-0.83-0.163.986.065.695.10
Tangible Book Value Per Share-5.06-3.98-0.191.041.170.35
Full-Time Employees470433-372355349
Price to Book Ratio-113.6329.4115.2313.8814.3810.79
Return on Assets-99.78-97.15-101.04-3.09-5.70-8.45
Return on Equity-760.01-702.97-335.82-8.65-15.81-24.19
Return on Invested Capital-5.94-8.96-140.12-0.910.48-1.02
Quick Ratio1.982.741.992.553.162.97
Current Ratio2.072.862.092.673.313.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-40.77-67.23-790.15-5.732.90-5.86
Depreciation6.896.946.876.076.066.06
Other Funds (Non Cash)18.5956.26452.3019.7318.5718.40
Funds from Operations-15.28-4.03-330.9820.0727.5418.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital10.97-40.22102.22-14.0112.14-6.56
Cash from Operating Activities-4.31-44.25-228.766.0739.6812.04
Capital Expenditures-1.30-25.02-10.66-0.60-0.19-0.13
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-27.56-134.97-0.901.61-2.04-6.47
Purchase of Investments-53.76-160.81-34.80-11.50-20.86-31.54
Sale Or Maturity of Investments26.2025.8533.8913.1118.8225.06
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-28.87-159.99-11.571.01-2.23-6.60
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock7.7613.37270.089.0016.108.69
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.7613.37270.089.0016.108.69
Proceedsfrom Stock Options7.7613.3710.139.0016.108.69
Issuance or Reduction of Debt, Net-62.10198.070.000.000.000.00
Change in Long Term Debt-62.10198.070.000.000.000.00
Issuance of Long Term Debt-0.39672.430.000.000.000.00
Reduction of Long Term Debt-61.72-474.370.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-54.34211.44270.089.0016.108.69
Exchange Rate Effect-0.02-1.37-1.27-0.410.352.23
Net Change in Cash-87.545.8228.4815.6653.9016.36
Free Cash Flow-5.62-44.27-229.435.4739.4911.91
Price to Free Cash Flow---74.2894.28293.33

Revenue breakdown

Bile Acid Medicines2024: 123.11M 2025: 161.31M
License and Other2024: 479.00K
Livmarli2024: 213.30M 2025: 360.01M
United States2024: 336.89M 2025: 521.31M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.06%6.5M54.1M720.99K
2026-10-1512.39%6.7M53.8M723.65K
2026-09-3012.98%7.0M53.8M682.58K
2026-09-1511.68%6.3M53.8M770.97K
2026-08-3111.47%6.2M53.8M783.17K
2026-08-1412.22%6.5M53.1M858.83K
2026-07-3112.90%6.8M52.9M987.93K
2026-07-1514.64%7.3M49.7M995.07K
2026-06-3015.06%7.5M49.7M1.00M
2026-06-1513.91%6.9M49.7M948.71K
2026-05-2913.23%6.6M49.6M987.15K
2026-05-1516.53%8.2M49.6M987.18K
2026-04-3016.63%8.4M50.6M800.78K
2026-04-1516.40%8.2M50.1M844.73K
2026-03-3115.28%8.1M52.7M884.67K
2026-03-1314.16%7.5M52.7M825.65K
2026-02-2714.46%7.6M52.7M795.54K
2026-02-1317.82%8.0M45.1M739.92K
2026-01-3017.17%7.8M45.4M761.49K
2026-01-1517.79%7.6M42.7M693.05K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call50.0041.6046.500.003.6780.000.000.904-0.5720.025
call55.0036.6041.500.003.2320.000.000.891-0.5560.027
call60.0031.5036.300.002.7200.000.000.876-0.5370.030
call65.0026.5031.300.002.3510.000.000.858-0.5130.033
call70.0021.6026.400.002.1760.000.000.836-0.4840.036
call75.0017.0021.800.001.6280.000.000.811-0.4550.040
call80.0012.0016.800.001.4770.000.000.774-0.4120.044
call85.008.0012.808.101.43323.000.000.725-0.3620.049
call90.004.509.303.901.21816.000.000.643-0.3210.055
call95.001.856.502.501.17519.000.000.519-0.4050.059
call1001.004.903.701.30011.000.000.420-0.4120.058
call1050.054.901.271.5312.000.000.363-0.4750.055
call1100.104.900.191.74922.008.000.333-0.5270.053
call1150.000.250.900.7769.000.000.063-0.0800.018
call1200.054.900.600.8789.000.000.049-0.0730.015
call1250.004.902.602.3111.000.000.276-0.6340.050
call1300.004.902.102.4421.000.000.268-0.6660.049
call1350.004.901.752.5962.000.000.258-0.6940.048
call1400.004.901.452.7412.000.000.249-0.7190.048
put50.000.004.900.004.4320.000.00-0.102-0.6500.027
put55.000.004.900.003.9260.000.00-0.116-0.6320.029
put60.000.004.900.003.4650.000.00-0.132-0.6100.032
put65.000.004.901.223.03810.000.00-0.151-0.5840.035
put70.000.004.902.552.6371.000.00-0.172-0.5530.038
put75.000.004.903.251.9961.000.00-0.189-0.4390.040
put80.000.054.901.001.68310.000.00-0.219-0.4080.044
put85.000.154.904.281.2889.000.00-0.278-0.3520.049
put90.000.953.602.800.95224.003.00-0.357-0.3110.055
put95.003.107.900.001.2590.000.00-0.481-0.4050.059
put1006.0010.8019.001.2485.000.00-0.585-0.3910.057
put10510.0014.800.001.3400.000.00-0.635-0.4600.055
put11014.5019.300.001.4180.000.00-0.669-0.5170.053
put11519.0023.800.001.5080.000.00-0.946-0.0580.016
put12024.0028.800.001.6850.000.00-0.952-0.0610.015
put12529.0033.800.001.8720.000.00-0.957-0.0630.013
put13033.6038.500.002.1530.000.00-0.960-0.0650.013
put13538.6043.500.002.3010.000.00-0.963-0.0670.012
put14043.6048.500.002.2820.000.00-0.965-0.0690.011

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-138-KCurrent report2026-10-12SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-09-288-KCurrent report2026-09-25SEC
2026-09-223Initial statement of beneficial ownership of securities2026-09-21SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-088-KCurrent report2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-06SCHEDULE 13GSEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.80M1
2026-100000
2026-09004.00M3
2026-08006.77M4
2026-07003.38M3
2026-06004.01M4
2026-0500218.94K1
2026-0400193.80K1
2026-03007.25M6
2026-02001.52M4
2026-019.00M13.22M11
2025-12008.14M4
2025-11003.50M1

Institutional holders

Manager% owned
Frazier Life Sciences Management, L.P.12.59%
Jupiter Topco LLC9.69%
BlackRock, Inc.7.20%
FMR LLC6.27%
PRICE T ROWE ASSOCIATES INC /MD/4.35%
VANGUARD PORTFOLIO MANAGEMENT LLC3.90%
VANGUARD CAPITAL MANAGEMENT LLC3.70%
STATE STREET CORP3.56%
Invesco Ltd.2.24%
GEODE CAPITAL MANAGEMENT, LLC2.23%

Funds

Fund% owned
NYLIM MacKay Convertible Fund36.66%
NYLIM VP MacKay Convertible Portfolio25.66%
Fidelity SAI Convertible Arbitrage Fund23.99%
Fidelity Convertible Securities Fund6.83%
Invesco Convertible Securities Fund4.10%
Janus Henderson High-Yield Fund3.04%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.70%
Fidelity Strategic Dividend and Income Fund2.50%
Strategic Advisers Fidelity U.S. Total Stock Fund2.07%
iShares Russell 2000 ETF2.00%

OakChart. MIRM. Cached 15 minutes.